1943P - Efficacy and safety of eribulin plus anlotinib and camrelizumab in advanced or metastatic retroperitoneal liposarcoma (RLPS) or leiomyosarcoma (RLMS): A single-center retrospective cohort study

Background

RLPS and RLMS are not sensitive to conventional chemotherapy. We evaluated the efficacy and safety of eribulin plus anlotinib and camrelizumab for RLMS and RLPS.

Methods

Patients (pts) with advanced/metastatic RLPS or RLMS treated with eribulin plus anlotinib and camrelizumab (Q3W) at Peking University Cancer Hospital Sarcoma Center were included in this retrospective analysis. Response (RECIST v1.1) was evaluated every 3 treatment cycles. Adverse event severity was graded per CTCAE v5.0.

Results

From December 17, 2020 to November 18, 2022, 60 pts (27 male; 33 female) were included. 22 pts had RLMS; RLPS subtypes were well-differentiated (n=9), de-differentiated (n=24), and myxoid (MLPS; n=5). Eribulin was given to 21 pts (35%) at 0.7–1.1 mg/m², and 39 (65%) at 1.1–1.4 mg/m².5 pts (RLMS, n=2; RLPS, n=3) were excluded from efficacy analyses due to drug intolerance and the COVID-19 pandemic. After a median of 5 cycles (range, 2–21), a partial response was observed in 15 pts (27.3%), stable disease in 27 (49.1%) and progressive disease in 13 (23.6%). The objective response rate (ORR) and disease control rate (DCR) were 27.3% and 76.4%, respectively. ORR and DCR in pts with RLMS were 42.1% and 84.2%, respectively; in pts with RLPS, they were 19.4% and 72.2%, respectively. After a median follow up of 11.3 months (mo), 10 pts had complete resection, 2 of whom had pathological complete response (1 with RLMS and 1 with MLPS); 3 other pts had locoregional recurrence after surgery. Median progression-free survival (mPFS) for the remaining 45 pts was 5.8 mo; mPFS for RLPS and RLMS subgroups were 5.5 and 6.2 mo, respectively. Any-grade treatment-related AEs (TRAEs) occurred in 51/60 pts (85.0%), with 22 (36.7%) experiencing grade ≥3 TRAEs. The most common TRAEs were neutropenia (58.3%), proteinuria (23.3%) and anorexia (23.3%). Due to AEs, 15 pts (25.0%) discontinued treatment and 6 (16.7%) reduced their eribulin dose.

Conclusions

Eribulin plus anlotinib and camrelizumab demonstrated clinically meaningful efficacy and a manageable safety profile in pts with advanced or metastatic RLPS or RLMS, especially in those with RLMS.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.